Background
Michael Becich, CEO and Co-Founder of Cache DNA, began his academic journey with degrees in bioengineering and applied mathematics from Stanford, followed by an MS/MBA program at Harvard focused on biotechnology. His career includes experiences at Illumina, NASA, and Octave Bioscience, where he honed his skills in bioinformatics and assay development. Partnering with James Banal, a postdoctoral fellow at MIT in Mark Bathe’s BioNanoLab, they founded Cache DNA to revolutionize molecular storage systems by addressing the challenges of instability, high costs, and limited access.
Why Cache DNA?
Michael’s motivation stems from a personal commitment to precision medicine, influenced by his family’s experiences with diseases like cancer and neurological disorders. “The journey towards a cure begins with samples,” Becich says. Cache DNA aims to store the biomolecules of today to unlock the possibilities of tomorrow, ensuring samples are preserved for extended periods and shared effectively across academic and industry partners to power research and clinical applications.
“The pressures of financial recovery for those managing precious longitudinal/cross-sectional sample collections (supported by finite grants and budgets) can detract from groundbreaking investigations,” Becich explains. By providing secure, stable, and cost-effective nucleic acid preservation solutions compatible with existing laboratory infrastructure, Cache DNA empowers researchers to utilize samples to their maximum potential—whether it be for oncology, rare genetic diseases, or pathogen screening—without paying a compounding penalty for storage.
Not only are freezers expensive, but they occupy a large footprint, consume electricity, and produce carbon emissions. With Cache’s room-temperature storage technology, space can be reclaimed for more productive means while promoting more environmentally and financially sustainable laboratory practices.
The StarFinder Lab Experience
Cache DNA discovered the StarFinder Lab program through an investor recommendation and saw it as a unique opportunity. The program offers access to the expertise of aMoon, a leading VC, and Roche, providing invaluable guidance and resources. “The program stands out due to its intimate support structure, enabling us to connect with stakeholders across Roche’s global portfolio,” Becich says. This focused support is crucial for navigating the complexities of the biotechnology space.
Looking Ahead
Michael and the Cache DNA team are enthusiastic about the collaboration with Roche and aMoon, which allows their scientists and engineers to directly engage with industry leaders. “The emphasis on transparency and trust within the program is vital for our product development,” Becich notes. They look forward to the transformative impact of this partnership, sharing a commitment to innovation and sustainability over the next nine months.